MURATA-MANUFACTURING
13.12.2021 02:02:15 CET | Business Wire | Press release
Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) has co-developed a new generation of RFID modules with Michelin that are embedded into tires. The robust passive RFID tags require no external power supply and will continue to operate while being driven on for extremely high mileages. This simple yet elegant technology delivers low cost and easy tire traceability throughout its entire lifespan, enabling the management of inventory logistics, aftermarket maintenance, and recycling operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211212005019/en/
“RFID technology is a key enabler to gain efficiency and optimise tire operations, but also to improve the customer experience while identifying tires and associating data. An embedded tag is the only way to identify tires, from the cradle to the grave, consistently,” said Mr. Jerôme Barrand, Michelin RFID program leader. “Thanks to a great collaboration with Murata, a new efficient and cost-effective solution has been developed, enabling Michelin to address a larger market. This new generation of RFID tags is already in more than four million Michelin tires. As the technology is also available, from now on, to any other tire manufacturer, this shall foster market adoption.”
Currently, Michelin uses the RFID tags in commercial vehicles, such as lorries, busses and passenger cars. Michelin is working towards expanding this roll out to 100% of the MICHELIN tires from 2024. Importantly, the company anticipates that key players in the market will embrace this technology for improved tire traceability.
“Murata will continue to improve technologies for innovative solutions and will contribute to tire management operations throughout its lifecycle and the enhancement of customer experience,” says Masamichi Ando, Senior Director of RFID Business Department at Murata.
Murata has extensive experience and knowledge of RF technology and downsizing. Improving the reliability compared to existing RFID tags while minimizing cost were critical factors when developing the tire embeddable RFID tag. Designed and manufactured by Murata, the RFID module is approximately the size of a grain of rice, measuring 1x1x6 mm. By inserting it into a simple spring antenna designed and manufactured by HANA Technologies, the RFID tag achieves the simplest communication architecture, enabling it to link to the tire ecosystem.
In addition to the supply of this RFID module, Murata will be able to offer its id-BridgeTM platform (RFID middleware), which processes and interprets the data transmitted from the tire embeddable RFID tag in conformance with ISO standards*.
For more information about the tire embeddable RFID tags, which are already in mass production, please visit: https://rfid.michelin.com/
*ISO is the International Organization for Standardization that issues international standards for various industries. ISO20910 specifies the general requirements and data structure for coding the tire embeddable RFID tag. ISO20912 specifies the test methods for validating the conformance of RFID enabled tires.
Murata in Brief
Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. For more information, visit Murata's website at www.murata.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211212005019/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom